Posted on March 23, 2021 by Sitemaster
According to a media release, issued earlier today by Novartis, the company has provided preliminary data about the results of the international, multi-center, Phase III, randomized, VISION trial, which has been evaluating the efficacy and safety of lutetium-177 PSMA-617, a targeted radioligand therapy, in treatment of men with progressive, PSMA-positive, metastatic, castration-resistant prostate cancer (mCRPC) … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, lutetium-177, mCRPC, metastatic, PSMA, PSMA-617 | 3 Comments »
Posted on December 19, 2019 by Sitemaster
Lu-177-PSMA usually improves survival
We’ve seen in a couple of small trials in Germany and Australia that Lu-177-PSMA seemed to provide better than expected survival. … READ MORE … -p>
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: Lu-177-PSMA, lutetium-177, metastatic, PSMA | 13 Comments »
Posted on July 16, 2019 by Sitemaster
A lot of people are hopeful that treatment with a new form of targeted nuclear radiation therapy — lutetium-177 PSMA 617 (177Lu PSMA) — will be able to significantly extend survival of men with metastatic, castration-resistant prostate cancer (mCRPC) … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, lutetium-177, mCRPC, metastatic, NOX66, PSMA | 1 Comment »
Posted on October 25, 2018 by Sitemaster
We have just been appraised of a randomized, double-blind, multi-center, Phase III clinical trial of the targeted, radiolabeled agent 177Lu-PSMA-617 (a form of “radioligand” therapy) in the treatment of metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, Lu-177, lutetium-177, metastatic, Phase III, PSMA, trial | 15 Comments »
Posted on July 2, 2018 by Sitemaster
According to a presentation given last week in San Francisco, lutetium-177 (177Lu) prostate-specific membrane antigen (PSMA) radioligand therapy has significant clinical activity in men with metastatic prostate cancer (as opposed to just in men with very late stages of prostate cancer). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: activity, lutetium, lutetium-177, outcome, radioligand | 11 Comments »
Posted on April 11, 2018 by Sitemaster
According to a recent media release, a company called Endocyte has reached agreement with the US Food and Drug Administration about the design of a pivotal Phase III clinical trial that will test the effectiveness and safety of 177Lu-PSMA-617 in men with recurrent, metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: efficacy, lutetium-177, outcome, Phase III, pivotal, PSMA-617, safety, trial | 4 Comments »
Posted on January 31, 2018 by Sitemaster
Some readers may have noticed that, late last week, the US Food and Drug Administration (FDA) approved a product known as lutetium Lu-177 dotatate or Lutathera for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: Lu-177, lutetium-177 | 1 Comment »
Posted on October 17, 2017 by Sitemaster
We have enthusiastically reported the encouraging outcomes of the early clinical trials of the radiopharmaceutical Lu-177-PSMA, most recently at this link. Based on reduction in PSA levels, it performs well. But medicines have no real benefit if all they do is treat PSA. We want medicines that increase survival. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, lutetium-177, mCRPC, metastatic, outcome, PSMA, survival | 8 Comments »
Posted on September 6, 2017 by Sitemaster
Targeted nuclear medicine has shown some impressive outcomes in several small studies, mostly conducted in Germany. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: Lu-177, lutetium-177, PSMA | 5 Comments »
Posted on January 12, 2017 by Sitemaster
An article by Strosberg et al. in today’s issue of the New England Journal of Medicine has nothing to do with prostate cancer at all; it’s all about a new form of treatment for certain types of advanced midgut cancer — but … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: lutetium-177, neuoendocrine, Treatment | 6 Comments »
Posted on February 22, 2016 by Sitemaster
There has been a good deal of optimism about the potential efficacy and safety of the radioisotope-labeled product known as prostate-specific membrane antigen-linked lutetium-177 (177Lu-PSMA) in the treatment of very late stage prostate cancer. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, Lu-177, lutetium-177, mCRPC, metastatic, PSMA, Treatment | 4 Comments »
THE "NEW" PROSTATE CANCER INFOLINK 